SCHEMBL277541

SCHEMBL277541

Oc1ccc2cncnc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.60
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
KMT2A Q03164 1/20 0.52
ESR2 Q92731 1/20 0.52
PDGFRB P09619 1/20 0.51
PDGFRA P16234 1/20 0.51
IMPDH2 P12268 2/20 0.43
PIK3CG P48736 1/20 0.42
TDO2 P48775 1/20 0.42
CYP17A1 P05093 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
BAZ1A Q9NRL2 1/20 0.40
HSD17B1 P14061 1/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinazoline SCHEMBL13837703 0.91 EGFR (0.69) EGFRMEN1ALDH1A1CASP1CASP7
Hydroquinone SCHEMBL8878778 0.85 EGFR (0.52) EGFRMEN1ALDH1A1CASP1CASP7
SCHEMBL27666932 0.85 ESR2 (0.54) EGFRMEN1KMT2AESR2PDGFRB
SCHEMBL276645 0.83 EGFR (0.60) EGFRESR2PDGFRBPDGFRAPIK3CG
SCHEMBL10923754 0.81 EGFR (0.49) EGFRESR2PDGFRBPDGFRAIMPDH2
Hydrochloric Acid SCHEMBL27897677 0.80 EGFR (0.56) EGFRESR2PDGFRBPDGFRAPIK3CG
SCHEMBL8641138 0.78 EGFR (0.64) EGFRIMPDH2TDO2BAZ1APIK3CD
SCHEMBL1403684 0.75 EGFR (1.00) EGFRMEN1ALDH1A1KMT2AIMPDH2
SCHEMBL18618545 0.75 EGFR (0.60) EGFRIMPDH2TDO2BAZ1APIK3CD
SCHEMBL21936740 0.75 EGFR (0.60) EGFRIMPDH2TDO2BAZ1APIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3386511-B2 METHODS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2024-03-20 EP claimed
EP-3433249-B1 BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST COUNCIL SCIENT IND RES (IN) 2022-11-09 EP claimed
EP-3027600-B1 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS NOVARTIS AG (CH) 2022-04-06 EP claimed
CN-107764905-B Detection method of quinazoline-7-ether compound and related substances thereof 江苏康缘药业股份有限公司 2020-07-14 CN claimed
CN-108697709-A Methods for treating huntington's disease PTC医疗公司 2018-10-23 CN claimed
CN-107764905-A A kind of ether compound of quinazoline 7 and its detection method about material 江苏康缘药业股份有限公司 2018-03-06 CN claimed
CN-107428729-A COMPOUNDS FOR THE TREATMENT OF CANCER 豪夫迈·罗氏有限公司 2017-12-01 CN claimed
WO-2016154694-A1 N-ACYLHYDRAZONE COMPOUNDS INHIBITING HISTONE DESACETYLASE ENZYMES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PRODUCING SAME UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRJ (BR) 2016-10-06 WO claimed
CN-101622252-A Substituted triazoles useful as AXL inhibitors RIGEL PHARMACEUTICALS INC 2010-01-06 CN claimed
US-20260102395-A1 INHIBITING HISTONE DEACETYLASE 6 EIKONIZO THERAPEUTICS, INC. (US) 2026-04-16 US disclosed
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof EIKONIZO THERAPEUTICS, INC. (US) 2026-03-31 US disclosed
US-20260055090-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2026-02-26 US disclosed
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20250250263-A1 INHIBITING HISTONE DEACETYLASE 6 (HDAC6) EIKONIZO THERAPEUTICS, INC. (US) 2025-08-07 US disclosed
WO-2002016352-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2002-02-28 WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2001077085-A1 QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2001-10-18 WO disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed
CN-1141633-A 4-heterocyclic substituted quinazoline derivatives, process for their preparation and their use as anticancer agents PFIZER (US) 1997-01-29 CN disclosed
US-3931298-A FROM A HYDROXYAROMATIC AND AMMONIA, GROUP 8-CYCLOHEXANONE CATALYST ETHYL CORPORATION (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 EGFR 4466/4885MEN1 4196/4885ALDH1A1 3032/4885
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof HDAC6, HDAC1, HDAC9 EGFR 1297/4885MEN1 4699/4885ALDH1A1 2216/4885
US-20260055090-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, CTTN EGFR 645/4885MEN1 3173/4885ALDH1A1 2666/4885
US-20260102395-A1 INHIBITING HISTONE DEACETYLASE 6 HDAC6, HDAC1, HDAC8 EGFR 2282/4885MEN1 4496/4885ALDH1A1 1511/4885
US-20250250263-A1 INHIBITING HISTONE DEACETYLASE 6 (HDAC6) HDAC6, HDAC1, HDAC9 EGFR 2951/4885MEN1 4221/4885ALDH1A1 1703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.